The ROE as of December 2024 (TTM) for BeyondSpring Inc. (BYSI) is 54.63%

According to BeyondSpring Inc.’s latest financial reports and current stock price. The company's current ROE is 54.63%. This represents a change of 297.01% compared to the average of 13.76% of the last 4 quarters.

BeyondSpring Inc. (BYSI) Historical ROE (quarterly & annually)

How has BYSI ROE performed in the past?

The mean historical ROE of BeyondSpring Inc. over the last ten years is 44.58%. The current 54.63% ROE has changed 22.54% with respect to the historical average. Over the past ten years (40 quarters), BYSI's ROE was at its highest in in the December 2018 quarter at 181.78%. The ROE was at its lowest in in the September 2018 quarter at -255.43%.

BeyondSpring Inc. (BYSI) ROE by Quarter and Year

Discovering the peaks and valleys of BeyondSpring Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BeyondSpring Inc. (BYSI) Average ROE

How has BYSI ROE performed in the past?

The current ROE of BeyondSpring Inc. (BYSI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

BeyondSpring Inc. (BYSI) ROE vs. Peers

How is BYSI’s ROE compared to its peers?

BeyondSpring Inc.’s ROE is greater than Surrozen, Inc. (-222.75%), less than Armata Pharmaceuticals, Inc. (89.12%), greater than Pasithea Therapeutics Corp. (-81.66%), greater than Oncternal Therapeutics, Inc. (-177.58%), greater than Aditxt, Inc. (-431.38%), greater than scPharmaceuticals Inc. (-314.97%), greater than Milestone Pharmaceuticals Inc. (-151.81%), greater than Oncolytics Biotech Inc. (-141.94%), less than Seres Therapeutics, Inc. (60.75%), greater than aTyr Pharma, Inc. (-56.83%), less than Kineta, Inc. (934.78%), less than Candel Therapeutics, Inc. (3.21%), less than MiNK Therapeutics, Inc. (76.05%), greater than Forte Biosciences, Inc. (-151.43%), greater than AlloVir, Inc. (-78.95%), less than Ocuphire Pharma, Inc. (0%), greater than Reviva Pharmaceuticals Holdings, Inc. (-30.19%), less than Protalix BioTherapeutics, Inc. (1.15%), greater than EyePoint Pharmaceuticals, Inc. (-30.89%), greater than SELLAS Life Sciences Group, Inc. (-43.01%), greater than null (-629.45%),

Build a custom stock screener for BeyondSpring Inc. (BYSI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BeyondSpring Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BeyondSpring Inc. (BYSI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BeyondSpring Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.